SHRX Sharp Therapeutics Corp.
Sharp Therapeutics Corp., a preclinical-stage drug discovery company, develops therapeutics for genetic diseases. The company engages in the development of the CoreX, a suite of biology technologies that allows the creation of sensitive assays mimicking the genetic disease state, enabling discovery of compounds that correct the mutational defect; AlloChem, a compound library which binds proteins allosterically; and Mine, a custom-built, cloud-distributed analytics platform that captures data for AlloChem compounds in CoreX assays. Sharp Therapeutics Corp. is headquartered in Pittsburgh, Pennsylvania.…
Industry Peers
BiotechnologyKey Statistics
About Sharp Therapeutics (CVE: SHRX)
›
Sharp Therapeutics (CVE: SHRX) is listed on the TSX Venture Exchange, where its shares trade in CAD. It belongs to the Biotechnology industry, part of the Healthcare sector.
The shares were at 1.370 CAD on 18 November 2026, down 67.4% over 52 weeks. Its 52-week range is 0.9100 CAD to 3.950 CAD: the price is 65.3% below the high and 50.5% above the low.
Its market capitalisation is 41.20M CAD.
Sharp Therapeutics reports an operating margin of 0.0%.
Its debt exceeds its cash by 2.15M USD. Its Piotroski F-score is 1 out of 9, a weak reading of its financial health. The next earnings report is expected on 26 November 2026.